Pulmonx Corporation (LUNG)
| Market Cap | 1.39B |
| Revenue (ttm) | 32.73M |
| Net Income (ttm) | -32.23M |
| Shares Out | 10.18M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $38.02 |
| Previous Close | $38.99 |
| Change ($) | -0.97 |
| Change (%) | -2.49% |
| Day's Open | 39.13 |
| Day's Range | 35.81 - 39.48 |
| Day's Volume | 797,991 |
| 52-Week Range | 35.81 - 69.48 |
REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today re...
REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will r...
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reporte...
REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...
Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company's Initial Public Offering Georgia Garinois-Melenikiotou and Thomas W. Burns Joined th...
Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1
REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment for patie...
REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor conferences.
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from Health Care ...
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for pat...
Pulmonx: Assessing The IPO
Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public offering priced above range. The deal priced...
Pulmonx, a maker of treatments for lung diseases including emphysema, priced its initial public offering at $19 a share, above its proposed price range of $17 to $18.
REDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a ...
Pulmonx, a maker of treatments for lung diseases including emphysema, upsized its planned initial public offering on Wednesday and raised the proposed price range, saying in a regulatory filing it will ...
About LUNG
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also prov... [Read more...]
| Industry Surgical and Medical Instrument Manufacturing | IPO Date Oct 1, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol LUNG |
Financial Performance
In 2020, Pulmonx's revenue was $32.73 million, an increase of 0.42% compared to the previous year's $32.60 million. Losses were -$32.23 million, 55.7% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Pulmonx stock is "Buy." The 12-month stock price forecast is 60.14, which is an increase of 58.18% from the latest price.